Xilio Therapeutics Inc
NASDAQ:XLO 4:00:00 PM EDT
| Market Cap (Intraday) | 33.06M |
| Current PE | N/A |
| Forward PE | N/A |
| 2yr Forward PE | N/A |
| 10-Day MA | $0.77 |
| 50-Day MA | $0.83 |
| 200-Day MA | $0.88 |
Xilio Therapeutics Inc Stock, NASDAQ:XLO
828 Winter Street, Suite 300, Waltham, Massachusetts 02451
United States of America
Phone: +1.857.524.2466
Number of Employees: 73
Description
Xilio Therapeutics, Inc. operates as a biotechnology company. It focuses on harnessing the immune system to achieve deep and durable clinical responses in cancer. The company uses its proprietary geographically precise solutions platform to rapidly engineer novel molecules, including cytokines and other biologics. Xilio Therapeutics was founded by John C. Williams and Ulrich Rodeck in June 2015 and is headquartered in Waltham, MA.